Cécile Chartier
Director/Board Member bei CELLECTIS S.A.
Profil
Cécile Chartier is currently working as a Director at Cellectis SA and as the Chief Scientific Officer at NextVivo, Inc. She holds a doctorate degree from Universite Louis Pasteur Strasbourg I.
Aktive Positionen von Cécile Chartier
Unternehmen | Position | Beginn |
---|---|---|
CELLECTIS S.A. | Director/Board Member | 27.06.2023 |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Cécile Chartier
Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Private Unternehmen | 1 |
---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |